Abstract:Vascular epidermal growth factor receptor-2 (VEGFR-2), as an important tyrosine transmembrane protein, plays an important role in regulating endothelial cell proliferation and migration, regulating angiogenesis and other biological functions. VEGFR-2 is aberrantly expressed in many malignant tumors, and it is also related to the occurrence, development, and growth of tumors and drug resistance. Currently, there are nine VEGFR-2 targeted inhibitors approved by US.FDA for clinical use as anticancer drugs. Due to the limited clinical efficacy and potential toxicity of VEGFR inhibitors, it is necessary to develop new strategies to improve the clinical efficacy of VEGFR inhibitors. The development of multitarget therapy, especially dual-target therapy, has become a hot research field of cancer therapy, which may provide an effective strategy with higher therapeutic efficacy, pharmacokinetic advantages and low toxicity. Many groups have reported that the therapeutic effects could be improved by simultaneously inhibiting VEGFR-2 and other targets, such as EGFR, c-Met, BRAF, HDAC, etc. Therefore, VEGFR-2 inhibitors with multi-targeting capabilities have been considered to be promising and effective anticancer agents for cancer therapy. In this work, we reviewed the structure and biological functions of VEGFR-2, and summarized the drug discovery strategies, and inhibitory activities of VEGFR-2 inhibitors with multi-targeting capabilities reported in recent years. This work might provide the reference for the development of VEGFR-2 inhibitors with multi-targeting capabilities as novel anticancer agents.

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Therapeutic Paradigm Of Dual Targeting Vegf And Pdgf For Effectively Treating Fgf-2 Off-Target Tumors

Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.

Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review

Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

Current status of drugs targeting PDGF/PDGFR

Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.

Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects

Multitarget Inhibitors Derived from Crosstalk Mechanism Involving VEGFR2.

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer